Fang Haiying, Wang Huiqin, Lv Hongxian
Department of Pediatrics, Jinhua Maternal and Child Health Care Hospital (Jinhua Women's and Children's Hospital), Jinhua, Zhejiang, China.
Br J Hosp Med (Lond). 2025 Jun 25;86(6):1-13. doi: 10.12968/hmed.2024.1016. Epub 2025 Jun 13.
Vitamin D plays a crucial role in regulating puberty development. Furthermore, it is closely associated with the onset and progression of precocious puberty. Therefore, this study aimed to investigate the effects of vitamin D supplementation on growth and development in girls with central precocious puberty (CPP) undergoing recombinant human growth hormone (rhGH) combined with gonadotropin-releasing hormone analogues (GnRH-a) therapy and to analyze its underlying mechanisms. This retrospective study analyzed the clinical data from 100 CPP girls who received rhGH combined with GnRH-a in Jinhua Maternal and Child Health Care Hospital between June 2020 and December 2022. Study participants were divided into the vitamin D supplementation group (VitD group, = 43) and the non-supplementation group (non-VitD group, = 57) according to whether vitamin D was supplemented during treatment. Growth and development indicators, including bone age/chronological age (BA/CA), predicted adult height (PAH), Tanner stage, sex hormone levels, and bone mineral density (BMD) of the left heel were compared between the two groups before treatment and 12 months after treatment. After 12 months of treatment, the VitD group demonstrated a significantly reduced BA/CA ratio compared to the non-VitD group ( = 0.002). The VitD group had a significantly higher PAH than the non-VitD group ( = 0.009). Furthermore, the comparison of the Tanner stage between the two groups showed a statistically significant difference ( = 0.033). Additionally, the estradiol (E), GnRH excitation test-follicle stimulating hormone (FSH) peak value and GnRH excitation test-luteinizing hormone (LH) peak value were significantly lower in the VitD group than in the non-VitD group ( < 0.001, = 0.014, < 0.001). Moreover, the BMD of the left heel in the VitD group significantly increased to that of the non-VitD group following 12 months of treatment ( = 0.005). Supplementation of vitamin D during rhGH combined with GnRH-a treatment further enhances the growth and development of CPP girls. This positive impact may be due to its crucial role in inhibiting the growth of breast epithelial cells, reducing sex hormone levels, and reducing treatment-induced BMD.
维生素D在调节青春期发育中起着至关重要的作用。此外,它与性早熟的发生和进展密切相关。因此,本研究旨在探讨补充维生素D对接受重组人生长激素(rhGH)联合促性腺激素释放激素类似物(GnRH-a)治疗的中枢性性早熟(CPP)女孩生长发育的影响,并分析其潜在机制。这项回顾性研究分析了2020年6月至2022年12月期间在金华市妇幼保健院接受rhGH联合GnRH-a治疗的100例CPP女孩的临床资料。根据治疗期间是否补充维生素D,将研究参与者分为维生素D补充组(VitD组,n = 43)和非补充组(非VitD组,n = 57)。比较两组治疗前和治疗12个月后的生长发育指标,包括骨龄/实足年龄(BA/CA)、预测成年身高(PAH)、 Tanner分期、性激素水平和左脚跟骨密度(BMD)。治疗12个月后,VitD组的BA/CA比值与非VitD组相比显著降低(P = 0.002)。VitD组的PAH显著高于非VitD组(P = 0.009)。此外,两组Tanner分期的比较显示差异有统计学意义(P = 0.033)。此外,VitD组的雌二醇(E)、GnRH兴奋试验-促卵泡生成素(FSH)峰值和GnRH兴奋试验-黄体生成素(LH)峰值均显著低于非VitD组(P < 0.001,P = 0.014,P < 0.001)。此外,治疗12个月后,VitD组左脚跟的BMD显著高于非VitD组(P = 0.005)。在rhGH联合GnRH-a治疗期间补充维生素D可进一步促进CPP女孩的生长发育。这种积极影响可能是由于其在抑制乳腺上皮细胞生长、降低性激素水平和减少治疗引起的骨密度方面的关键作用。